Lisata Therapeutics Announces Mutual Termination of License Agreement with Qilu Pharmaceutical for Certepetide
Lisata Therapeutics, Inc. (LSTA)
Company Research
Source: GlobeNewswire
BASKING RIDGE, N.J., Jan. 27, 2026 (GLOBE NEWSWIRE) -- Lisata Therapeutics, Inc. (Nasdaq: LSTA) (“Lisata” or the “Company”), a clinical-stage pharmaceutical company developing innovative therapies for the treatment of advanced solid tumors and other serious diseases, today announced that it has mutually terminated the February 2021 Exclusive License and Collaboration Agreement with Qilu Pharmaceutical Co., Ltd. (“Qilu”). The original agreement, negotiated and implemented with CEND Therapeutics and assumed by Lisata as part of its acquisition of CEND Therapeutics in 2022, granted Qilu exclusive rights to develop and commercialize certepetide, Lisata's proprietary iRGD cyclic peptide product candidate, in the Greater China region including Mainland China, Hong Kong, Macau, and Taiwan. This action results in all licenses and other rights granted to Qilu reverting to Lisata. “We appreciate the collaboration and the work performed by Qilu with certepetide over the past few years. As a r
Show less
Read more
Impact Snapshot
Event Time:
LSTA
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
LSTA alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
LSTA alerts
High impacting Lisata Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
LSTA
News
- Halper Sadeh LLC Encourages PEN, RAPT, LSTA Shareholders to Contact the Firm to Discuss Their RightsPR Newswire
- $HAREHOLDER ALERT: The M&A Class Action Firm Is Investigating The Merger--PEN, RAPT, NATH, and LSTAPR Newswire
- All-Cash Buyout Sparks Breakout Move in Biotech Name [Globe and Mail, The (Toronto, Canada)]Globe and Mail, The
- LSTA Stock Alert: Halper Sadeh LLC is Investigating Whether the Sale of Lisata Therapeutics, Inc. is Fair to ShareholdersBusiness Wire
- Lisata Therapeutics (NASDAQ:LSTA) had its "hold" rating reaffirmed by analysts at Brookline Capital Management.MarketBeat
LSTA
Earnings
- 11/6/25 - Beat
LSTA
Sec Filings
- 1/27/26 - Form 8-K
- 1/21/26 - Form SC14D9C
- 1/21/26 - Form 8-K
- LSTA's page on the SEC website